Registries in idiopathic inflammatory myopathies

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 729-734

  Lundberg, Ingrid E ^a   Svensson, John ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Idiopathic inflammatory myopathies; Myositis; Registry

Indexed keywords

CREATINE KINASE; GLUCOCORTICOID; RITUXIMAB;

ANTISYNTHETASE SYNDROME; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE REGISTRY; GASTROINTESTINAL DISEASE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCLUSION BODY MYOSITIS; INTENTION TO TREAT ANALYSIS; JUVENILE DERMATOMYOSITIS; LUNG DISEASE; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE FUNCTION; MYOSITIS; OXYGEN CONSUMPTION; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

HUMANS; INTERNATIONAL COOPERATION; MYOSITIS; PROGNOSIS; REGISTRIES; TREATMENT OUTCOME;

EID: 84885305175     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434667.55020.e1     Document Type: Review

References (24)

1. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875
2. Too CL, Yahya A, Murad S, et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anticitrullinated protein antibody-positive rheumatoid arthritis: Results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther 2012; 14:R89
3. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. Br Med J 1998; 317:180-181
4. EkströmK, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-970
5. .Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45:676-683
6. .Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet Disord 2012; 13:103
7. .Barnabe C, Joseph L, Belisle P, et al. Prevalence of autoimmune inflammatory myopathy in the first nation's population of Alberta, Canada. Arthritis Care Res (Hoboken) 2012; 64:1715-1719
8. Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: Age, sex and regional differences. Ann Rheum Dis 2009; 68:1192-1196
9. .Furst DE, Amato AA, Iorga SR, et al. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 2012; 46:496-505
10. Bernatsky S, Panopalis P, Pineau CA, et al. Healthcare costs of inflammatory myopathies. J Rheumatol 2011; 38:885-888
11. .Limaye V, Hakendorf P, Woodman RJ, et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012; 42:191-198
12. Airio A, Pukkala E, Isomä ki H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 1995; 22:1300-1303
13. Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes Control 1995; 6:9-13
14. Sigurgeirsson B, Lindelö f B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N Engl J Med 1992; 326:363-367
15. .Limaye V, Luke C, Tucker G, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33:965-971
16. Askling J, Baecklund E, Granath F, et al. Antitumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68:648-653
17. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1414-1420
18. .Mathiesen PR, OrngreenMC, Vissing J, et al. Aerobic fitness after JDM-A longterm follow-up study. Rheumatology (Oxford) 2013; 52:287-295
19. Mariette X, Gottenberg J-E, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries. Rheumatology 2011; 50:222-229
20. Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: Results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011; 38:1436-1440
21. Martin N, Krol P, Smith S, et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 2011; 50:137-145
22. Couderc M, Gottenberg JE, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: Results from the AIR registry. Rheumatology (Oxford) 2011; 50:2283-2289
23. .Betteridge Z, Tansley S, Gunawardena H, et al. Clinical phenotypes of Caucasian adult and juvenile dermatomyositis patients with anti-MDA5 autoantibodies [Abstract]. Arthritis Rheum; 64:1673
24. .Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (antithreonyl-TRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012; 91:206-211